Monitor for actual execution of this sale on Form 4 filings. A large insider sale by a 10% holder could signal reduced conviction, but the stock has strong analyst consensus (93% bullish) and a history of positive post-report drift. Watch for any subsequent Form 4 filings to confirm the sale.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 11 $30.00entry
- T+1 · 3mo ago −2.07%α −2.32% · $29.38
- T+5 · 3mo ago +10.00%α +10.40% · $33.00
- T+20 · 2mo ago +20.40%α +21.46% · $36.12
- T+60 · 13d ago −35.00%α −34.86% · $19.50
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cambrian BioPharma Inc, a 10% stockholder of Faeth Therapeutics, filed a Form 144 notice of intent to sell 130,142 shares of common stock, with an estimated aggregate market value of approximately $3.64 million. The shares were acquired in a private placement in January 2020. This represents a notable insider selling signal from a major shareholder, though the sale is not yet executed and the filing is an advance notice of intent.
Key Facts
- Cambrian BioPharma Inc, a 10% stockholder, filed a Form 144 to sell 130,142 shares of Faeth Therapeutics common stock.
- The estimated aggregate market value of the proposed sale is approximately $3.64 million based on a 07/22/2026 trade date.
- Shares were acquired in a private placement on 01/10/2020.
- The filing date is 08/11/2026, and the sale is planned through Fidelity Brokerage Services LLC.
Financial Impact
Proposed sale of 130,142 shares valued at approximately $3.64 million, representing about 0.5% of the company's $738M market cap.
Risk Factors
- Insider selling by a major shareholder may indicate reduced confidence in near-term prospects.
- The sale is not yet executed; the filing only signals intent, and the insider may not follow through.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-005879 |
| Document: 0001959173-26-005879-index.html | 0001959173-26-005879 |
| Document: 0001959173-26-005879.txt | 0001959173-26-005879 |
Track record
12 reports on FTH
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $10.03 Now $10.03 −0.00% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $12.68 to $12.92 Now $10.03 −20.90% ▲ +1.89% +2.26% vs SPY
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $12.68 to $12.92 Now $10.03 −20.90% ▲ +1.89% +2.26% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $19.65 to $19.99 Now $10.03 −48.96% ▲ +1.73% +0.08% vs SPY
- Oct 27, 202620d ago 3 Neutral 2/10 Entry $19.20 to $18.75 Now $10.03 −47.76% ▼ −2.34% −1.96% vs SPY
- Oct 27, 202620d ago 8-K Neutral 2/10 Entry $19.11 to $19.20 Now $10.03 −47.51% ▲ +0.47% +0.13% vs SPY
- Sep 15, 20268w ago 3 Neutral 2/10 Entry $34.24 to $35.13 Now $10.03 −70.71% ▲ +2.60% +1.47% vs SPY
- Aug 11, 202613w ago 144 Bearish 5/10 Viewing Entry $30.00 to $29.38 Now $10.03 +66.57% ▲ +2.07% +2.32% vs SPY
- Aug 4, 202614w ago 8-K Neutral 3/10 Entry $25.50 to $24.59 Now $10.03 −60.67% ▼ −3.57% −3.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers